Notably, the T2R14 agonist lidocaine has demonstrated anticancer effects [28,29,30], leading to clinical trials evaluating its efficacy for solid tumors such as breast cancer [31] and HNSCC [32]. This evidence concerns the gene TAS2R14 and head and neck squamous cell carcinoma.